Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA

Rebecca Earnest(Yale University), Rockib Uddin(Massachusetts General Hospital), Nicholas Matluk(Riverview Psychiatric Center), Nicholas Renzette(Jackson Laboratory), Katherine J. Siddle(Broad Institute), Christine Loreth(Broad Institute), Gordon Adams(Broad Institute), Christopher H. Tomkins-Tinch(Broad Institute), Mary E. Petrone(Yale University), Jessica E. Rothman(Yale University), Mallery I. Breban(Yale University), Robert T. Koch(Yale University), Kendall Billig(Yale University), Joseph R. Fauver(Yale University), Chantal B. F. Vogels(Yale University), Sarah E. Turbett(Massachusetts General Hospital), Kaya Bilgüvar(Acıbadem University), Bony De Kumar(Yale University), Marie L. Landry(Yale University), David R. Peaper(Yale University), Kevin Kelly(Jackson Laboratory), Greg Omerza(Jackson Laboratory), Heather Grieser(Riverview Psychiatric Center), Sim Meak(Riverview Psychiatric Center), John Martha(Riverview Psychiatric Center), Hannah H. Dewey(Jackson Laboratory), Susan Kales(Jackson Laboratory), Daniel Berenzy(Jackson Laboratory), Kristin Carpenter‐Azevedo(Rhode Island Department of Health), Ewa King(Rhode Island Department of Health), Richard C. Huard(Rhode Island Department of Health), Sandra Smole(Massachusetts Department of Public Health), Catherine Brown(Massachusetts Department of Public Health), Timelia Fink(Massachusetts Department of Public Health), Andrew S. Lang(Massachusetts Department of Public Health), Glen R. Gallagher(Massachusetts Department of Public Health), Pardis C. Sabeti(Broad Institute), Stacey Gabriel(Broad Institute), Bronwyn MacInnis(Broad Institute), New England Variant Investigation Team(Tufts University), Ryan Tewhey(Tufts University), Mark D. Adams(Broad Institute), Daniel J. Park(Broad Institute), Jacob E. Lemieux(Broad Institute), Nathan D. Grubaugh(Yale University)
medRxiv
October 7, 2021
Cited by 73Open Access
Full Text

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant quickly rose to dominance in mid-2021, displacing other variants, including Alpha. Studies using data from the United Kingdom and India estimated that Delta was 40-80% more transmissible than Alpha, allowing Delta to become the globally dominant variant. However, it was unclear if the ostensible difference in relative transmissibility was due mostly to innate properties of Delta's infectiousness or differences in the study populations. To investigate, we formed a partnership with SARS-CoV-2 genomic surveillance programs from all six New England US states. By comparing logistic growth rates, we found that Delta emerged 37-163% faster than Alpha in early 2021 (37% Massachusetts, 75% New Hampshire, 95% Maine, 98% Rhode Island, 151% Connecticut, and 163% Vermont). We next computed variant-specific effective reproductive numbers and estimated that Delta was 58-120% more transmissible than Alpha across New England (58% New Hampshire, 68% Massachusetts, 76% Connecticut, 85% Rhode Island, 98% Maine, and 120% Vermont). Finally, using RT-PCR data, we estimated that Delta infections generate on average ∼6 times more viral RNA copies per mL than Alpha infections. Overall, our evidence indicates that Delta's enhanced transmissibility could be attributed to its innate ability to increase infectiousness, but its epidemiological dynamics may vary depending on the underlying immunity and behavior of distinct populations.


Related Papers

No related papers found

Powered by citation graph analysis